The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)

RECRUITING

Study Site 1107, Cleveland

RECRUITING

Study Site 1100, Canton

RECRUITING

Study Site 1106, Houston

RECRUITING

Study Site 1103, Duarte

RECRUITING

Study Site 1110, La Jolla

RECRUITING

Study Site 1202, São José do Rio Preto

RECRUITING

Study Site 1612, Plovdiv

RECRUITING

Study Site 1613, Sofia

RECRUITING

Studyy Site 1610, Sofia

RECRUITING

Study Site 1341, Düsseldorf

RECRUITING

Study Site 1340, Leipzig

RECRUITING

Study Site 1653, Budapest

RECRUITING

Study Site 1650, Debrecen

RECRUITING

Study Site 1651, Székesfehérvár

RECRUITING

Study Site 1901, Jerusalem

RECRUITING

Study Site 1902, Petah Tikva

RECRUITING

Study Site 1900, Tel Litwinsky

RECRUITING

Study Site 1384, Milan

RECRUITING

Study Site 1383, Rozzano

RECRUITING

Study Site 1385, Turin

RECRUITING

Study Site 1771, Kaunas

RECRUITING

Study Site 1700, Olsztyn

RECRUITING

Study Site 1411, Madrid

RECRUITING

Study Site 1414, Valencia

RECRUITING

Study Site 1580, Huddinge

RECRUITING

Study Site 1581, Lund

RECRUITING

Study Site 1440, London

RECRUITING

Study Site 1446, Manchester